Study to assess if adding Carboplatin before surgery improves Tumor response in Non metastatic TNBC patients .

Assessment of pathological complete response rates with the addition of carboplatin to the sequential taxane-anthracycline chemotherapy in patients with non metastatic triple negative breast cancer - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/091252

Enrollment

Registered

2025-07-21

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Paclitaxel and Carboplatin for 4 cycles followed by Adriamycin and cyclophosphomide for 4 cycles: 3 weekly carboplatin was added to the Sequential Taxane-anthracycline chemotherapy vs t

Eligibility

Inclusion criteria

Inclusion criteria: Patients with histopathologically diagnosed Triple negative breast carcinoma with Early stage breast cancer ( More than T1c-T3 , N0-N1 , M0) and Locally advanced Breast cancer (T4,N2-N3,M0). Eastern Coperative Oncology group score : 0-1. Patients who are medically fit for Chemotherapy. Patients with normal baseline laboratory values. Patients giving informed consent.

Exclusion criteria

Exclusion criteria: Male Breast cancer Patients with Ejection fraction less than 45 percent Patients with upfront metastatic disease.

Design outcomes

Primary

Measure	Time frame
Pathological Complete ResponseTimepoint: After completion of 8 cycles of Neoadjuvant chemotherapy (6 months)	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Viji V Julian

MADRAS MEDICAL COLLEGE & RAJIV GANDHI GOVERNMENT GENERAL HOSPITAL

drkannanj@gmail.com9444143950

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026